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Background: Pain relief during labour is a topic of major interest in the Netherlands. Epidural analgesia is
considered to be the most effective method of pain relief and recommended as first choice. However its uptake by
pregnant women is limited compared to other western countries, partly as a result of non-availability due to logistic
problems. Remifentanil, a synthetic opioid, is very suitable for patient controlled analgesia. Recent studies show that
epidural analgesia is superior to remifentanil patient controlled analgesia in terms of pain intensity score; however
there was no difference in satisfaction with pain relief between both treatments.
Methods/design: The proposed study is a multicentre randomized controlled study that assesses the
cost-effectiveness of remifentanil patient controlled analgesia compared to epidural analgesia. We hypothesize that
remifentanil patient controlled analgesia is as effective in improving pain appreciation scores as epidural analgesia,
with lower costs and easier achievement of 24 hours availability of pain relief for women in labour and efficient
pain relief for those with a contraindication for epidural analgesia.
Eligible women will be informed about the study and randomized before active labour has started. Women will be
randomly allocated to a strategy based on epidural analgesia or on remifentanil patient controlled analgesia when they
request pain relief during labour. Primary outcome is the pain appreciation score, i.e. satisfaction with pain relief.
Secondary outcome parameters are costs, patient satisfaction, pain scores (pain-intensity), mode of delivery and
maternal and neonatal side effects.
The economic analysis will be performed from a short-term healthcare perspective. For both strategies the cost of
perinatal care for mother and child, starting at the onset of labour and ending ten days after delivery, will be registered
and compared.
Discussion: This study, considering cost effectiveness of remifentanil as first choice analgesia versus epidural analgesia,
could strongly improve the care for 180.000 women, giving birth in the Netherlands yearly by giving them access to
pain relief during labour, 24 hours a day.
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Epidural analgesia is considered to be the most effective
method of pain relief during labour and is recommended
as first method of pain relief by the Dutch Societies of
Gynecologists and Anesthetists [1,2]. In the Netherlands
its uptake by pregnant women in labour of all ethnicities
is still limited (11.3% in 2008 but in the last years in-
creasing with 1-2% per year), compared with other west-
ern countries, partly as a result of non-availability due to
logistic problems. This is an undesirable situation, espe-
cially since the number of women asking for pain relief
during labour is increasing. There is also need for a safe
alternative for women who cannot receive epidural anal-
gesia because of contraindication for epidural analgesia.
The availability and uptake of epidural analgesia during
labour varies significantly between countries, for ex-
ample approximately 20% of women in the UK and 58%
of women in the USA use this form of pain relief. There
is considerable variation in the availability of epidural an-
algesia within the UK as in the Netherlands [3].
There are situations in which epidural analgesia is
contra-indicated. In these cases intramuscular or intra-
venous opioids provide an alternative. Variation is also
present in the use of opioids during labour, reported
numbers range from 5-66%. In the last update of the
Cochrane review “Parenteral opioids for maternal pain
management in labour” the authors recommend a prag-
matic large randomized controlled trial to compare pain
relief using an opioid to other methods of pain relief to
collect data on maternal satisfaction, co-interventions
and maternal and neonatal outcome prospectively [4].
At present in the Netherlands, pain relief during labour
is of major interest and an important topic for pregnant
women, health care providers and politicians, as is pointed
out in the publication of the Steering Committee Preg-
nancy and Birth installed by the Dutch Ministry of Health,
Welfare and Sports [3]. One of the advices is that all
Dutch women in labour should have access to adequate
pain relief. The working party of the Dutch guideline "Pain
relief during labour" recommends using remifentanil pa-
tient controlled analgesia (PCA) only in controlled setting
and recommends a large trial. Nevertheless, over one third
of Dutch hospitals use remifentanil PCA on labour wards.
Possible explanations are that the presence of an
anesthetist for this type of analgesia is not required and
that administration of remifentanil is quicker and less in-
vasive than epidural analgesia. Literature study reveals that
this does not only apply to the Dutch obstetrical system,
which differs from other western countries because of a
higher percentage of women under the care of community
midwives and of home-births.
The most commonly used opioid is intramuscular
pethidine. However, its analgesic effectiveness is widely
challenged [5-7]. Remifentanil is a synthetic opioid(anilidopiperidine) with direct agonist action specifically on
μ-opioid receptors [8]. The rapid onset and offset of the
drug make remifentanil very suitable for administration via
patient controlled analgesia (PCA), which can be used for
analgesia during labour. Placental transfer of remifentanil
does occur but appears to be rapidly metabolized, redistrib-
uted, or both. There were no adverse neonatal or maternal
effects, only mild maternal sedation and respiratory
changes [9]. There have been multiple clinical studies on
the use of remifentanil in women in labour [10-22].
Two studies address pain relief scores of remifentanil
PCA (patient controlled analgesia) compared to epidural
analgesia, although both had limitations. Volmanen et al.
limited the observation period to only one hour. Douma
et al. recorded pain relief scores as a secondary outcome
measure in a study powered to investigate difference in
pain scores. Both studies showed that in terms of pain
scores (pain-intensity), epidural analgesia is superior tot
remifentanil PCA. However, there was no difference in the
pain appreciation scores between both treatments [23,24].
Methods/Design
Aims
The objective of this study is to test the hypothesis that
remifentanil PCA is as effective as epidural analgesia
with respect to patient satisfaction and pain appreciation
scores, with lower costs and possibly the benefit of easier
achievement of 24 hours availability of pain relief for
women in labour.
Participants/eligibility criteria
All pregnant women in the participating hospitals will be
informed of the trial at antenatal visits in the third tri-
mester. They can participate in the trial if they are
healthy or have a mild systemic disease (ASA physical
status 1 or 2) and are 18 years or older with a gestational
age >32 weeks. Randomization takes place before active
labour has started, at antenatal visits in the third trimes-
ter or at admission on the ward before induction. Exclu-
sion criteria are hypersensitivity for any of the products
used or if there is a contraindication for epidural
analgesia.
Procedures, recruitment, randomization, collection of
baseline data
The study will be a multicentre randomized controlled
study. The study will be performed within the Dutch Con-
sortium for Studies in Women’s Health and Reproductiv-
ity. Participating hospitals can be district, teaching or third
referral hospitals. Before entry into the study, women are
informed about the aims, methods, reasonably anticipated
benefits and potential hazards of the study. They are
informed that their participation is voluntary and that they
may withdraw consent to participate at any time during
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In every centre an independent gynaecologist will be avail-
able for more detailed information both for patients and
colleagues if required.
After giving sufficient information, written informed
consent is obtained. The consent form must be signed
before performance of any study-related activity. After
obtaining informed consent women will be randomized
and will be informed on the assigned method of pain re-
lief before labour starts (as in usual care). They are only
given pain relief during labour at their request or if a
medical reason should arise.
Randomization will be stratified for centre and parity.
We will apply block randomization with a fixed block
size. Randomization will be performed through a web-
based database located in the central data collection unit
in the AMC in Amsterdam. Women will be randomly
allocated to receive remifentanil PCA or epidural anal-
gesia when they request pain relief during labour. There
will be no blinding, as this is not possible due to the na-
ture of the two treatment methods.
Baseline demographic, past obstetric and medical his-
tories, including ASA physical status, will be recorded
for all women.
All details of delivery and health care received in the
ten days after delivery are recorded in the case record
form that is accessible through a website http://www.
studies-obsgyn.nl/ravel.Interventions
After giving informed consent women will be rando-
mized to receive remifentanil PCA or epidural analgesia
during labour if they request pain relief during labour.
Parturients randomized to intravenous remifentanil will
receive a 30 μg loading dose and boluses of 30 μg with a
3 minute lockout time. We decided on a flexible bolus
dose. In case of insufficient pain relief the bolus can be
increased to 40 μg or decreased to 20 μg in case of ex-
cessive side effects. Parturients randomized to epidural
analgesia will receive epidural analgesia according to
local protocol.Outcome measures
The main outcome parameter is pain appreciation, i.e.
satisfaction with pain relief. Women will be asked to ex-
press their level of satisfaction with pain relief every
15 min during the first hour and hourly after that. This
will be scored on a visual analogue scale (VAS) ranging
from 1 (highly dissatisfied) to 10 (highly satisfied).
Secondary endpoints are pain scores, scored on a vis-
ual analogue scale ranging from 1 (no pain) to 10 (worst
imaginable pain), maternal side effects, mode of delivery
and maternal and neonatal mortality and morbidity.Economic evaluation
General consideration
The results of the study will provide insight on whether
remifentanil PCA in women in labour will reduce costs
as compared to epidural analgesia, assuming there will
be equivalence in pain appreciation of both methods. At
present, no clinical study has been published or under-
taken to investigate this issue. An estimation of costs for
remifentanil PCA versus epidural analgesia shows a de-
crease of 64 euro per patient. The difference in costs is
due to the extra costs of anesthetic staff and nurses,
required when epidural analgesia is given.
Cost analysis
Economic analysis
The economic analysis will be performed from a short-
term healthcare perspective. Anticipating on equality in
pain appreciation scores the economic analysis will be a
cost minimization analysis. For both strategies the cost of
perinatal care for mother and child, starting at the onset of
labour and ending ten days after delivery, will be registered
and compared (without discounting). The costs consist of
costs of delivery/childbirth (course and mode of delivery),
postnatal maternal care (hospitalization, outpatient visits),
neonatal care (admission to NICU/neonatology ward, out-
patient visits) and primary care (midwife, general practi-
tioner, maternity care).
Volumes of hospital care are measured prospectively
alongside the clinical study in all participating centres as
part of the case record form. Health resource use outside
the hospital will be recorded by questionnaires filled out
by the patients. Costs of delivery/childbirth will be based
on cost price analysis. Other resource use (hospital days,
outpatient visits and primary care) will be valued using
standard prices [25].
Follow up of women and infants
Details of admission of women and newborns will be
recorded as will maternal and neonatal complications.
Long term follow up is at present not part of this study.
Statistical issues
Sample size
The sample size is calculated based on the primary out-
come measure pain appreciation. We hypothesize that
there is no difference in pain appreciation with the two
sided test (alfa = 0.05, power (1-beta = 0.9). In this non-
inferiority design in each group 102 women have to be
treated to exclude a potential clinical relevant difference
of 10% (10 point scale, estimated SD 2.2). Allowing for
10% and 30% cross-over/ non-compliance in the control
group and experimental group respectively, 568 patients
are required. We estimate that in the group of pregnant
women who are willing to participate in the study 50%
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whole Dutch pregnant population, which is known for a
low uptake of pain relief during labour. Therefore 1136
women have to be randomized. In case of missing data
on the primary endpoint, we will extend the number of
women to be recruited accordingly.
Data analysis
Data will be analyzed according the intention to treat
principle. First, the remifentanil and epidural group will
be compared. Relative risks and 95% confidence inter-
vals will be calculated for the relevant outcome mea-
sures. Categorical variables will be tested with the Chi-
square test or Fisher’s exact test. Continuous variables
will be tested with the Mann–Whitney U test. Time to
delivery will be assessed using Kaplan-Meier analysis. In
case of equivalence between outcomes, the analysis will
be repeated on a par protocol basis. Subsequently,
planned subgroup analysis will be done for nulliparous
versus parous women, previous caesarean section, pre-
term labour (32–34 weeks and 34–37 weeks) and term
labour (37–42 weeks), spontaneous versus induced
labour, maternal educational level, maternal age (under
35 years versus over 35 years) and multiple pregnancy.
We will then use decision analysis to evaluate which
intervention strategy, i.e. remifentanil or epidural anal-
gesia is preferred in women who need analgesia during
labour.
Interim analysis
No interim analysis will be performed. Because of the
suggested design of the trial where equivalence is
expected all 1136 women have to be randomized in
order to achieve sufficient power. Both remifentanil PCA
and epidural analgesia are widely used in the Nether-
lands as pain relief during labour and no adverse events
have been recorded to date.
Serious Adverse Events (SAEs) and Suspected Unex-
pected Serious Adverse Reactions (SUSARs) will be
reported to a Data Safety Monitoring Committee (DSMC).
The DSMC can order to perform an interim analysis and,
if indicated, terminate the trial prematurely.
Ethical considerations
This study is approved by the National Central Commit-
tee on Research involving Human Subjects (CCMO -
NL34262.058.10.), by the ethics committee of the Leiden
University Medical Centre (Ref. No. P10-240) and by the
boards of management and ethics committees of all par-
ticipating hospitals.
Discussion
In the Netherlands uptake of epidural analgesia is lower
than in surrounding western European countries. Thiscan be partly due to our obstetrical system; a large
number of women under the care of community mid-
wives and about 25% of all births take place at home.
Epidural analgesia is recommended as first method of
pain relief by the Dutch Societies of Gynecologists
and Anesthetists. In daily practice not every labour
ward in the Netherlands has 24 hour availability of
epidural analgesia. One of the alternatives is remifen-
tanil PCA. Over one third of all hospitals use remi-
fentanil as pain relief during labour. With this study
we aim to test the hypothesis that remifentanil PCA
and epidural analgesia are equivalent in pain appreci-
ation with possible fewer costs. The outcome of this
study could improve the care for over 180.000
women giving birth in the Netherlands yearly.Abbreviations
ASA: American Society of Anesthesiologists; PCA: Patient controlled analgesia;
DSMB: Data safety monitoring board.
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